Companies / United Kingdom
Shire Acquires New River Pharmaceuticals
February 2007 | FDI AlertUK-based drugmaker is to purchase US-based New River Pharmaceuticals, in a deal worth US$2.6bn as it attempts to consolidate its position in the lucrative attention-deficit hyperactivity disorder (ADHD) market.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
